Mark A. Rubin   Professor of Pathology and Laboratory Medicine

  • +1 646 962 6166


Please visit Dr. Rubin's Lab Web Site

Prostate Cancer
The focus of Dr. Rubin#146;'s laboratory based research during the past decade has been the development of molecular biomarkers capable of distinguishing indolent from aggressive prostate cancer. He has contributed more than 170 peer-reviewed publications, predominantly in the area of prostate cancer, to the scientific literature. He holds multiple United States and international patents for molecular biomarkers. Over the immediate past few years he has been the principal investigator of three NIH sponsored RO1 grant awards, a U01 grant, a Prostate SPORE project and a Department of Defense Idea Award, all in the area of prostate cancer progression. His research relies on close collaboration with scientists and physician scientists in urology, medical oncology, and molecular biology. His laboratory has used a variety of techniques including RT-PCR, laser capture microdissection, high density tissue microarrays, SMP arrays, tiling arrays, and cNDA expression arrays in combination with clinical and morphologic parameters to identify significant associations. Some of his more significant work published in Nature and JAMA identified novel biomarkers including hepsin, pim-1 kinase, ERG, MTA1 Jagged 1, EZH2 and alpha-methlyacyl-CoA racemase. His ability to develop a translational research team led to the landmark discovery identifying fusion of the TMPRSS2 and ETS families of transcription factors in prostate cancer. These translocations were discovered by applying a novel bioinformatics approach. These translocations are believed to be the most common translocations yet described in any solid tumor. The TMPRSS2-ETS gene fusion appears to be one of the earliest events involving prostate cancer invasion, leading to the over expression of the fused ETS gene in an androgen-regulated manner. The patent rights are shared between the University of Michigan and the Brigham and Women#146;s Hospital and Genprobe has licensed the rights to commercially develop urine and tissue based tests. Dr. Rubin#146;'s Laboratory, working in close collaboration with investigators from Sweden and Dr. Todd Golub at the Broad Institute, have also recently developed a potential drug target for TMPRSS2-ETS fusion prostate cancer. These ongoing studies have the potential to influence the clinical care of the approximately 300,000 men diagnosed with prostate cancer each year in the United States.


Sort by

Selected publications


Sort by

Grants awarded



full name

  • Dr. Mark A. Rubin,

primary email



Primary Affiliation

  • Weill Cornell Medical College, Cornell University